Dalbavancin

In plain language

Dalbavancin is a long-acting antibiotic for serious skin infections by Gram-positive bacteria, sold as Dalvance. It is given as two intravenous infusions, one week apart, instead of daily dosing.

It is a modified cousin of vancomycin with a fatty side chain that anchors it to blood proteins, stretching its half-life to about two weeks. In trials the two-dose schedule matched a week or more of daily vancomycin.

For students

Dalbavancin is a semi-synthetic lipoglycopeptide (about 1,817 Da) derived from A40926, a teicoplanin-like glycopeptide from Nonomuraea. An amide-linked fatty chain (3-dimethylamino-1-propylamide on the mannose) raises albumin binding and protein-binding-driven volume of distribution, yielding a terminal half-life of roughly 14 days.

Approved in 2014 for acute bacterial skin and skin-structure infections, the DISCOVER 1 and DISCOVER 2 randomized trials (n=1,312 combined) established non-inferiority of the two-dose regimen (1,000 mg day 1, 500 mg day 8) versus 7-10 days of twice-daily vancomycin. It is active against MRSA and most resistant Gram-positive organisms; MIC creep among coagulase-negative staphylococci and rare vanA-type enterococci is a laboratory curiosity more than a clinical limitation to date.

For researchers and instructors

Biochemistry. A40926's teicoplanin-like scaffold with a core heptapeptide differing from vancomycin's at position 1 and 3 is the starting point; acylation is the single deliberate medicinal-chemistry move to convert a daily drug into a weekly one.

Pharmacology. Two infusions one week apart; no dose adjustments except severe renal impairment scenarios; long tissue concentrations support its use in osteomyelitis and endocarditis in observational series, though these are off-label.

Human evidence. DISCOVER 1 and DISCOVER 2 established non-inferiority to vancomycin for ABSSSI; subsequent real-world and registry data support its outpatient parenteral antibiotic role.

Teaching point. A clean demonstration that half-life, not potency, was the limiting property of the glycopeptide class, and how that insight enables outpatient antibiotic therapy.